Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer.

Share This Post

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, who have progressed on or after a prior platinum-containing regimen.

In the GARNET Trial (NCT02715284), a multicenter, multicohort, open-label trial in patients with advanced solid tumours, efficacy was assessed depending on cohort (A1). 71 patients with dMMR recurrent or advanced endometrial cancer who progressed on or after a platinum-containing treatment were included in the efficacy population. Patients were given 500 mg of dostarlimab-gxly intravenously every three weeks for four doses, then 1,000 mg intravenously every six weeks.

Overall response rate (ORR) and duration of response (DOR) were the primary efficacy outcomes, as determined by a blinded independent central review (BICR) in accordance with RECIST 1.1. The ORR was confirmed to be 42.3 percent (95 percent CI: 30.6 percent , 54.6 percent ). The response rate was 12.7 percent for complete responses and 29.6 percent for incomplete responses. With 93.3 percent of patients having durations of less than six months, the median DOR was not met (range: 2.6 to 22.4 months, ongoing at last assessment).

In 34 percent of individuals who received dostarlimab-gxly, serious side effects occurred. Sepsis, acute renal injury, urinary tract infection, abdominal discomfort, and pyrexia were among the serious adverse responses experienced by more than 2% of patients. Fatigue/asthenia, nausea, diarrhoea, anaemia, and constipation were the most prevalent side effects (20%). Anemia and elevated transaminases were the most common grade 3 or 4 adverse events (2%). Pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis are all immune-mediated adverse responses that might occur.

You may like to read : Cancer treatment in India

Dostarlimab-gxly 500 mg every 3 weeks is the recommended dose and schedule (doses 1 through 4). Starting three weeks following dosage 4, dosing is increased to 1,000 mg every six weeks until illness progression or intolerable toxicity. Dostarlimab-gxly should be delivered as a 30-minute intravenous infusion.

Reference :

Check details here.

Take second opinion on endometrial cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form